Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis

torstai 17. syyskuuta 2026 päivittänyt: Chuan Qin

The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis. The study will also explore whether adding terfenadine may help improve disease-related outcomes.

Researchers will compare participants who receive terfenadine plus standard first-line disease-modifying therapy with participants who receive standard first-line disease-modifying therapy alone.

Participants will:

Be randomly assigned to receive either terfenadine plus standard first-line disease-modifying therapy or standard first-line disease-modifying therapy alone.

Take terfenadine 60 mg once daily at bedtime for 1 month if assigned to the terfenadine group.

Attend study visits during screening, treatment, and follow-up over 12 months. Have physical examinations, vital sign checks, laboratory tests, electrocardiograms, imaging assessments, neurological evaluations, and collection of blood, stool, and cerebrospinal fluid samples at scheduled visits.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that can cause neurological disability and disease progression. Current disease-modifying therapies can reduce relapses and MRI disease activity, but limitations remain in preventing disability progression and promoting remyelination or neuroprotection.

Terfenadine is a histamine H1 receptor antagonist. Preclinical evidence suggests that histamine signaling may be involved in immune and inflammatory processes relevant to MS. This study will evaluate the safety and tolerability of terfenadine as an adjunct to standard first-line disease-modifying therapy and explore its potential clinical effects in people with MS.

This is a single-center, open-label, randomized controlled clinical trial. Approximately 100 participants will be enrolled and randomly assigned in a 2:1 ratio to a terfenadine treatment group or a control group. Participants in the terfenadine group will receive terfenadine 60 mg orally once daily at bedtime for 1 month in addition to standard first-line disease-modifying therapy. Participants in the control group will receive standard first-line disease-modifying therapy alone.

Participants will be followed for 12 months. Study assessments will include physical examinations, vital signs, laboratory tests, electrocardiograms, imaging examinations, neurological and functional assessments, quality-of-life assessments, and collection of blood, stool, and cerebrospinal fluid samples at scheduled visits. Safety will be assessed throughout the study by recording and following adverse events and by reviewing relevant clinical and laboratory findings.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

100

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

  • Kiina
    • Hubei
      • Wuhan, Hubei, Kiina, 430030
        • Rekrytointi
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Päätutkija:
          • Daishi Tian
        • Päätutkija:
          • Chuan Qin
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  1. Male or female participants aged 18 to 65 years, inclusive.
  2. Diagnosis of multiple sclerosis (MS) according to the 2024 revised McDonald diagnostic criteria.
  3. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.
  4. Participants must be able to understand the study requirements and provide written informed consent. If applicable, informed consent may be provided by the participant's legally authorized representative.

Exclusion Criteria:

  1. Use of drugs that may interact with terfenadine through CYP3A4 inhibition, including certain azole antifungal agents or macrolide antibiotics.
  2. Congenital long QT syndrome, atrioventricular block, abnormal baseline QTc interval (>450 ms in males or >470 ms in females), hypokalemia or hypomagnesemia, or concomitant use of drugs known to prolong the QT interval.
  3. Significant hepatic dysfunction.
  4. Active or clinically significant infection.
  5. Secondary demyelinating diseases of the central nervous system.
  6. Vascular, genetic, metabolic, neoplastic, toxic, or other diseases that may cause central nervous system demyelination or neurological symptoms that could interfere with study assessments.
  7. Myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association (NYHA) class IV heart failure within 12 weeks before screening.
  8. Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  9. Inability or unwillingness to comply with the study follow-up schedule or study procedures.
  10. Contraindication to lumbar puncture.
  11. Inability or unwillingness to undergo the required magnetic resonance imaging (MRI) examinations.
  12. Participation in another clinical trial within 3 months before screening.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Terfenadine Plus Standard First-line Disease-Modifying Therapy
Participants will receive standard first-line disease-modifying therapy plus terfenadine 60 mg orally once daily at bedtime for 1 month, followed by observation through 12 months.
Lääke: Terfenadine
Terfenadine will be administered orally at a dose of 60 mg once daily at bedtime for 1 month as add-on therapy to standard first-line disease-modifying therapy.
Lääke: Standard First-line Disease-Modifying Therapy
Participants will receive standard first-line disease-modifying therapy for relapsing-remitting multiple sclerosis according to routine clinical practice.
Active Comparator: Standard First-line Disease-Modifying Therapy Alone
Participants will receive standard first-line disease-modifying therapy alone according to routine clinical practice and will be followed for 12 months.
Lääke: Standard First-line Disease-Modifying Therapy
Participants will receive standard first-line disease-modifying therapy for relapsing-remitting multiple sclerosis according to routine clinical practice.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Safety and tolerability of terfenadine during the treatment period
Aikaikkuna: Baseline through 1 month
Safety and tolerability will be assessed by the incidence and severity of adverse events and serious adverse events, as well as changes or clinically significant abnormalities in vital signs, physical examinations, clinical laboratory tests, electrocardiograms, and imaging examinations.
Baseline through 1 month

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Safety and tolerability during the 12-month follow-up period
Aikaikkuna: Baseline through 12 months
Safety and tolerability will be assessed by the incidence and severity of adverse events and serious adverse events, as well as changes or clinically significant abnormalities in vital signs, physical examinations, clinical laboratory tests, electrocardiograms, and imaging examinations.
Baseline through 12 months
Change from baseline in cerebrospinal fluid white blood cell count
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid white blood cell count will be measured at baseline, Month 1, and Month 12, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in cerebrospinal fluid albumin quotient
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid albumin quotient will be measured at baseline, Month 1, and Month 12, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in cerebrospinal fluid neurofilament light chain (NfL)
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid neurofilament light chain (NfL) level will be measured at baseline, Month 1, and Month 12 in pg/mL, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in cerebrospinal fluid oligoclonal bands (OCB)
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid oligoclonal bands (OCB) will be assessed at baseline, Month 1, and Month 12, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in cerebrospinal fluid kappa free light chain (kFLC)
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid kappa free light chain (kFLC) level will be measured at baseline, Month 1, and Month 12 in mg/L, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in cerebrospinal fluid IgG index
Aikaikkuna: Baseline, Month 1, and Month 12
Cerebrospinal fluid IgG index will be measured at baseline, Month 1, and Month 12, and the change from baseline will be evaluated.
Baseline, Month 1, and Month 12
Change from baseline in serum neurofilament light chain (NfL)
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, and Month 12
Serum neurofilament light chain (NfL) levels will be measured at baseline and during follow-up. Changes in serum NfL from baseline will be evaluated at Month 1, Month 3, Month 6, and Month 12.
Baseline, Month 1, Month 3, Month 6, and Month 12
Change from baseline in Expanded Disability Status Scale (EDSS) score
Aikaikkuna: Baseline, Month 1, Month 6, and Month 12
Neurological disability will be assessed using the Expanded Disability Status Scale (EDSS), which ranges from 0 to 10, with higher scores indicating greater disability and a worse outcome. The change in EDSS score from baseline will be evaluated at Month 1, Month 6, and Month 12.
Baseline, Month 1, Month 6, and Month 12
Change from baseline in Timed 25-Foot Walk (T25FW) walking speed
Aikaikkuna: Baseline, Month 3, Month 6, and Month 12
Walking function will be assessed using the Timed 25-Foot Walk (T25FW). The change in T25FW walking speed from baseline will be evaluated at Month 3, Month 6, and Month 12.
Baseline, Month 3, Month 6, and Month 12
Change from baseline in Nine-Hole Peg Test (9HPT) completion time
Aikaikkuna: Baseline, Month 3, Month 6, and Month 12
Upper limb motor function will be assessed using the Nine-Hole Peg Test (9HPT). The change in the time required to complete the 9HPT from baseline will be evaluated at Month 3, Month 6, and Month 12.
Baseline, Month 3, Month 6, and Month 12
Change from baseline in Symbol Digit Modalities Test (SDMT) score
Aikaikkuna: Baseline, Month 6, and Month 12
Cognitive function will be assessed using the Symbol Digit Modalities Test (SDMT), which ranges from 0 to 110, with higher scores indicating better cognitive processing speed. The change in SDMT score from baseline will be evaluated at Month 6 and Month 12.
Baseline, Month 6, and Month 12
Change from baseline in Multiple Sclerosis Functional Composite (MSFC) score
Aikaikkuna: Baseline, Month 6, and Month 12
Overall functional status will be assessed using the Multiple Sclerosis Functional Composite (MSFC), a standardized composite measure of neurological function based on the Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test. The MSFC score is expressed as a standardized z-score, with higher scores indicating better functional performance. The change in MSFC score from baseline will be evaluated at Month 6 and Month 12.
Baseline, Month 6, and Month 12
Change from baseline in EQ-5D-5L score
Aikaikkuna: Baseline, Month 1, and Month 12
Health-related quality of life will be assessed using the 5-Level EuroQol 5-Dimension questionnaire (EQ-5D-5L). The descriptive system consists of five dimensions, each rated from 1 to 5, with higher dimension scores indicating more severe problems. The EQ-5D-5L responses may be converted to an index value using the applicable value set, with higher index values indicating better health-related quality of life. The change in EQ-5D-5L score from baseline will be evaluated at Month 1 and Month 12.
Baseline, Month 1, and Month 12
Confirmed disability progression (CDP) rate at Month 6
Aikaikkuna: Baseline to Month 6
Confirmed disability progression will be evaluated at Month 6. CDP will be defined as an increase in EDSS score of at least 1.0 point for participants with a baseline EDSS score of 5.5 or lower, or at least 0.5 point for participants with a baseline EDSS score greater than 5.5, or an increase of at least 20% in T25FW completion time or 9HPT completion time.
Baseline to Month 6
Annualized relapse rate at Month 12
Aikaikkuna: Baseline through Month 12
Disease relapse will be assessed throughout the study, and the annualized relapse rate will be evaluated through Month 12. The annualized relapse rate at Month 12 will be compared between the terfenadine treatment group and the active comparator group.
Baseline through Month 12
MRI T2 lesion activity at Month 12
Aikaikkuna: Baseline and Month 12
Brain and spinal cord MRI findings will be evaluated at Month 12. The assessment will include the number of new or enlarging T2 hyperintense lesions, changes from baseline in cumulative T2 lesion number and lesion volume, and the proportion of participants without new T2 hyperintense lesions.
Baseline and Month 12
Gadolinium-enhancing T1 lesions on brain MRI at Month 12
Aikaikkuna: Baseline and Month 12
Brain MRI findings will be evaluated at Month 12. The assessment will include the change from baseline in the number of gadolinium-enhancing T1 lesions and the proportion of participants without gadolinium-enhancing lesions.
Baseline and Month 12

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Chuan Qin

Tutkijat

  • Päätutkija: Chuan Qin, Tongji Hospital

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Lauantai 15. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Lauantai 30. lokakuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 30. lokakuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Sunnuntai 6. syyskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 17. syyskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 18. syyskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 18. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 17. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • TJ-IRB202607023

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

Individual participant data will not be shared with other researchers because the study data are intended for analysis by the research team and publication of the study results only.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa